Journal of Isfahan Medical School

Journal of Isfahan Medical School

Study of the quality of life of patients with myasthenia gravis in Isfahan.

Document Type : Original Article(s)

Authors
Keivan Basiri 1
Pegah Sadeghi Asl 2
Matin Basiri 3
1 Associate Professor of Neurology, Isfahan Neuroscience Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
2 MSc, Department of Nursing, Health Research Center, Isf.C., Islamic Azad University, Isfahan, Iran
3 Medical Student, Isfahan Neuroscience Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
10.48305/jims.v44.i875.1526
Abstract
Introduction: As an autoimmune disease, myastheniagravis leads to muscle weakness with inefficient transmission of neuromuscular junction, and with symptoms of ptosis, diplopia, dysphagia, shortness of breath, it reduces the quality of life of patients and in severe cases can be life threatening. Considering the importance of quality of life the present study was reviewed and compiled.
Method :This research is of a descriptive type, after randomly selecting 95 patients and holding educational classes to raise awareness about this disease, information was collected through a demographic questionnaire that includes age, sex, education, marital status, and the sf36 questionnaire.
Findings: The average quality of life of patients was equal to 50.45 with a standard deviation of 17.87, which indicates that the mean quality of life of patients is at an average level. The lowest average in quality of life was in the dimension of physical performance with a mean of 23.37 and a standard deviation of 36.43, and the highest mean was in the dimension of general health with a mean of 55.63 and a standard deviation of 17.87.
Also, there was no statistically significant relationship between patients' quality of life and demographic characteristics (P<0.05).
Conclusion: the burden of the disease has a significant negative impact on the quality of life of patients with myastheniagravis, which has negative effects on many aspects of well-being, including physical, mental, social health,the importance of attention and planning is mandatory for these patients.

Highlights

Keivan Basiri: Google Scholar, PubMed 

Pegah Sadeghi Asl: Google Scholar

Matin Basiri: Google Scholar, PubMed 

Keywords
Myasthenia gravis
Ptosis
Diplopia
Quality of life
Subjects
1.     Haridy N, Khedr E, Hasan A, Maghraby A, Abdelmohsen E, Aly A. Myasthenia gravis with achalasia secondary to thymoma: a case report and literature review. Egypt J Neurol Psychiatry Neurosurg 2023; 59: 34.
2.     Garcia-Garcia J, Díaz-Maroto I, Martínez-Martín A, Pardal-Fernández JM, Segura T. A series of patients with refractory myasthenia gravis. Neurologia (Engl Ed) 2023; S0213-4853(20)30293-0.
3.     Itani M, Goldman-Gollan Y, Ezell K, Mohanna M, Sabbagh S, Mears C, et al. Thymoma and myasthenia gravis: an examination of a paraneoplastic manifestation. Cureus 2023; 15(2): e34828.
4.     Dewilde S, Qi C, Phillips G, Iannazzo S, Janssen F. Association between Myasthenia Gravis Activities of Daily Living (MG-ADL) and EQ-5D-5L utility values: the additional effect of efgartigimod on utilities. Adv Ther 2023; 40: 1818–29.
5.     Zhang D, Luo L, Lu F, Li B, Lai X. Transcriptional landscape of myasthenia gravis revealed by weighted gene co-expression network analysis. Front Genet 2023; 14: 1106359.
6.     Lazaridis K, Tzartos SJ. Myasthenia gravis: autoantibody specificities and their role in MG management. Front Neurol 2020; 11: 596981.
7.     Chang C, Chen YK, Chiu HC, Yeh JH. Changes in physical fitness and body composition associated with physical exercise in patients with myasthenia gravis: a longitudinal prospective study. J Clin Med 2021; 10(17): 403131.
8.     Kanikannan M, Reddy P, Mathukumalli N, Yareeda S, Borgohain R. Impact of thymectomy on crisis incidence and quality of life amongst generalised myasthenia gravis patients. Neurol India 2022; 70(6): 2427–31.
9.     Ganeshgouda M, Ashish KD, Debashish CH, Arun A, Vineet KT, Sujata R. Clinical profile and quality of life in myasthenia gravis using MGQOL15R (Hindi): an Indian perspective. Ann Indian Acad Neurol 2023; 26(4): 441–6.
10.  Mohamed RA, Mohamed ES, Basiouny MA, Hamoda IM, Hanoura ES, Elhenedi EI, et al. Effect of two different rehabilitation approaches on pulmonary functional tests, neuromuscular functions and quality of life in juvenile myasthenia gravis: a randomized controlled trial. Medicina (Kaunas) 2022; 58(3): 374.
11.  Montazeri A, Goshtasbi A, Vahdani Nia MS. Translation, reliability and validity of the Persian version of the SF-36 questionnaire [in Persian]. Payesh. 2005; 5(1): 49–56.
12.  Saccà F, Barnett C, Vu T, Peric S, Phillips G, Zhao S, et al. Efgartigimod improved health-related quality of life in generalized myasthenia gravis: results from a randomized, double-blind, placebo-controlled, phase 3 study (ADAPT). J Neurol 2023; 270(4): 2096–105.
13.  Cutter G, Xin H, Aban I, Burns T, Allman PH, Farzaneh-Far R, et al. Cross-sectional analysis of the Myasthenia Gravis Patient Registry: disability and treatment. Muscle Nerve 2019; 60(6): 707–15.
14.  Fan X, Xing C, Yang L, Wang J, Feng L. Fatigue, self-efficacy and psychiatric symptoms influence the quality of life in patients with myasthenia gravis in Tianjin, China. J Clin Neurosci 2020; 79: 84–9.
15.  Hoffmann S, Ramm J, Grittner U, Kohler S, Siedler J, Meisel A. Fatigue in myasthenia gravis: risk factors and impact on quality of life. Brain Behav 2016; 6(10): e00538.
16.  Porras L, Homedes C, Alberti M, Santamaria V, Casasnovas C. Quality of life in myasthenia gravis and correlation of MG-QOL15 with other functional scales. J Clin Med 2022; 11(8): 2189.
17.  Scheel-Thomsen J, Vinge L, Harbo T, Andersen H. A population-based follow-up study of maximal muscle strength and mobility in patients with myasthenia gravis. Neuromuscul Disord 2022; 32(4):3 05–12.
18.  Wu X, Li R, Ye X, Wang N. Reduced quality of life in myasthenia gravis patients: a study on 185 patients from China. Front Neurol 2023; 13: 1072861.
19.  Jeong IA, Min J, Kang Y, Kim J, Choi M, Seok J, et al. Factors associated with quality of life of people with myasthenia gravis. PLoS One 2018; 13(11): e0206754.
20.  Nagane Y, Murai H, Imai T, Yamamoto D, Tsuda E, Minami N, et al. Social disadvantages associated with myasthenia gravis and its treatment: a multicentre cross-sectional study. BMJ Open 2017; 7(2): e013278.
21.  Kotan V, Kotan Z, Aydin B, Taşkapilioğlu O, Karli H, Yalvaç H, et al. Psychopathology, psychosocial factors and quality of life in patients with myasthenia gravis. J Neurol Sci Turk 2016; 33(3): 482–93.
22.  Beeching F, Lecchi A, Riccitelli GC. Female gender and quality of life outcomes in myasthenia gravis: a systematic review and meta-analysis. Ther Adv Neurol Disord 2025; 18: 17562864251344742.
Journal of Isfahan Medical School
Volume 44, Issue 875
2nd Week,October
September and October 2026
Pages 1526-1532

  • Receive Date 21 November 2025
  • Accept Date 08 September 2026